- Home
- INV vs VALN Comparison
INV vs VALN Comparison
Compare INV & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- VALN
- Stock Information
- Founded
- INV 2015
- VALN 2012
- Country
- INV United States
- VALN France
- Employees
- INV N/A
- VALN N/A
- Industry
- INV
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INV
- VALN Health Care
- Exchange
- INV NYSE
- VALN Nasdaq
- Market Cap
- INV 615.9M
- VALN 595.2M
- IPO Year
- INV N/A
- VALN 2021
- Fundamental
- Price
- INV $9.18
- VALN $7.44
- Analyst Decision
- INV Strong Buy
- VALN Strong Buy
- Analyst Count
- INV 1
- VALN 2
- Target Price
- INV $16.00
- VALN $17.00
- AVG Volume (30 Days)
- INV 43.5K
- VALN 81.7K
- Earning Date
- INV 03-04-2025
- VALN 03-20-2025
- Dividend Yield
- INV N/A
- VALN N/A
- EPS Growth
- INV N/A
- VALN N/A
- EPS
- INV N/A
- VALN N/A
- Revenue
- INV $988,000.00
- VALN $176,817,979.00
- Revenue This Year
- INV $2,784.42
- VALN $22.73
- Revenue Next Year
- INV $215.34
- VALN $11.39
- P/E Ratio
- INV N/A
- VALN N/A
- Revenue Growth
- INV 4.88
- VALN N/A
- 52 Week Low
- INV $8.55
- VALN $3.62
- 52 Week High
- INV $18.75
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- INV N/A
- VALN 60.56
- Support Level
- INV N/A
- VALN $6.62
- Resistance Level
- INV N/A
- VALN $8.42
- Average True Range (ATR)
- INV 0.00
- VALN 0.46
- MACD
- INV 0.00
- VALN 0.05
- Stochastic Oscillator
- INV 0.00
- VALN 69.85
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.